Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its latest quarterly report later this week. Market watchers are anticipating strong performance driven by the continued success of Lilly's blockbuster treatments, particularly its insulin portfolio. However, there are also concerns about potent